Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Artiva Biotherapeutics (NASDAQ:ARTV) from a hold rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Several other research analysts have also recently weighed in on ARTV. Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. TD Cowen lowered shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Jefferies Financial Group lowered shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a research report on Thursday. Needham & Company LLC cut shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Monday, October 19th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Hold” and a consensus target price of $24.80.

Artiva Biotherapeutics Trading Down 0.9%

Shares of Artiva Biotherapeutics stock opened at $4.19 on Friday. Artiva Biotherapeutics has a 12-month low of $2.96 and a 12-month high of $14.53. The company has a market cap of $204.85 million, a price-to-earnings ratio of -1.27 and a beta of 2.40. The company’s 50-day moving average price is $8.11 and its 200-day moving average price is $7.96.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.63). On average, sell-side analysts predict that Artiva Biotherapeutics will post -2.71 earnings per share for the current year.

Insider Buying and Selling

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 23,463 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $7.20, for a total value of $168,933.60. Following the transaction, the chief executive officer owned 1,519,606 shares in the company, valued at approximately $10,941,163.20. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jennifer Bush sold 8,370 shares of the business’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $6.84, for a total value of $57,250.80. Following the transaction, the chief operating officer owned 366,159 shares in the company, valued at approximately $2,504,527.56. This represents a 2.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 137,048 shares of company stock worth $1,086,167. Company insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of ARTV. Squarepoint Ops LLC purchased a new stake in shares of Artiva Biotherapeutics during the second quarter valued at approximately $144,000. Spark Investment Management LLC bought a new stake in shares of Artiva Biotherapeutics during the second quarter valued at approximately $160,000. Alyeska Investment Group L.P. increased its position in shares of Artiva Biotherapeutics by 173.6% during the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock valued at $2,654,000 after acquiring an additional 173,615 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in Artiva Biotherapeutics in the 2nd quarter worth approximately $2,910,000. Finally, 5AM Venture Management LLC purchased a new position in Artiva Biotherapeutics in the 2nd quarter worth approximately $22,827,049.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.